Our findings suggest that TFAP2B overexpression might help to identify NSCLC patients with a poor prognosis and could therefore serve as a potential prognostic biomarker and therapeutic target for lung cancer. This evidence concerns the gene TFAP2B and non-small cell lung carcinoma.